ABUS vs XRAY · P/E 5.4, rev $6.2M vs rev $3.68B
Arbutus Biopharma Corp (ABUS) versus Dentsply Sirona Inc (XRAY) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Dentsply Sirona Inc (XRAY) is a medical instruments & supplies company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported XRAY revenue for 2025-12-31 was $3.68B. Net income was -$598.0M. Revenue was down 3.0% from 2024-12-31 to 2025-12-31. XRAY currently screens at market cap $2.01B.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. XRAY currently screens at market cap $2.01B.
Not investment advice. Open the ABUS and XRAY stock pages for the full models.
Not investment advice.